Currently browsing author

admin, Page 15

Exclusive: Sysco sees U.S. bird flu hurting egg supply up to 18 months

By Anjali Athavaley NEW YORK (Reuters) – Food distributor Sysco Corp said on Friday that a record U.S. outbreak of avian flu would limit its supply of eggs and chickens that lay them for nine to 18 months, based on information provided to the company by its suppliers. Sysco is the biggest U.S. food distributor, whose clients include restaurants, hotels and hospitals. The company is discussing options with its customers, including creating alternative menu items during the period, a Sysco spokesman said in an email. It is too soon to tell whether the supply squeeze will have a material impact on financial results, spokesman Charley Wilson said.

How Democrats Are Fighting For Moms Every Day

Today, moms across the country will be treated to brunches, cards, flowers, and just generally the appreciation they so fully deserve. The range of ways we show our love for mothers will be as varied and diverse as the families celebrating. Of course, moms deserve more than just one day a year. Families have always relied on mom, but it may be…

Can peppermint sooth your stomach?

Article written by Coleanse Pills. Many studies suggest that peppermint oil to be effective for pain, indigestion, gas and treating bloated feeling …

Gilead first-quarter profit doubles on strong hepatitis C drug sales

By Deena Beasley LOS ANGELES (Reuters) – Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates. Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. “We want to stick very closely to therapeutic areas we are in today,” Gilead Chief Operating Officer John Milligan said on a conference call. Excluding items, Gilead earned $2.94 per share in the first quarter, beating the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S. The company’s shares, which fell 1.8 percent in regular trading, rose 2 percent to $102.52 after hours.

Designer molecule lowers HIV levels: trial results

This meant the designer molecule dubbed 3BNC117 may be best used in combination with other drugs, said the team — while highlighting the promise of a new, immunotherapy-based approach to fighting HIV. “This represents potentially a new class of drugs with activity against HIV,” study co-author Marina Caskey of New York's Rockefeller University told AFP. So-called monoclonal antibodies like 3BNC117 which are cloned from a single parent immune cell, hold the promise of actually killing HIV-infected cells. The new agent, cloned from a cell taken from an HIV-positive person, was given to 12 uninfected volunteers and 17 infected with HIV.